1 domain / 2 areas / 2 specializations
Cayman Chemical
Data updated
Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
Established supplier and CDMO platform (with Cayman Pharma) providing cGMP API manufacturing, including psychedelic compounds for clinical-trial pathways and analytical support.
Manufacturing Snapshot
Established CDMO / ManufacturerScope & Capabilities
Supply Use Cases
GxP / Compliance
Facilities & Access
Combined US and Czech manufacturing footprint via Cayman Chemical and Cayman Pharma.
Capacity Notes
API manufacturing materials describe annual capacity plus scale-up capability for multi-step synthesis programs.
Supported Substances
Cayman API materials cite cGMP psilocybin and psilocin for clinical trials, with development listings including 3,4-MDMA and N,N-DMT.
Quick Facts
- Website
- Visit